COT Cotinga Pharmaceuticals Inc

Critical Outcome Technologies Inc. (COTI) (TSX VENTURE:COT) announced today that
it has received conditional consent from the TSX Venture Exchange (TSXV) to
extend the expiry date of 11,250,000 common share purchase warrants (Warrants)
issued as part of three tranches of a non-brokered private placement on March
23, April 9 and April 26, 2012 respectively. Each Warrant entitled its holder to
purchase one common share of the Company at an exercise price of $0.30 per share
for a period of 18 months from the date of issue. 


The expiry dates have been amended as follows:



----------------------------------------------------------------------------
 Warrant Issue Date           New Expiry Date                               
----------------------------------------------------------------------------
 March 23, 2012               5:00 pm EDT on April 23, 2015                 
----------------------------------------------------------------------------
 April 9, 2012                5:00 pm EDT on May 9, 2015                    
----------------------------------------------------------------------------
 April 26, 2012               5:00 pm EDT on May 26, 2015                   
----------------------------------------------------------------------------



The New Expiry Dates of the Warrants will be reduced to a period of 21 days if,
for any ten consecutive trading days during the unexpired term of the Warrant
(the "Premium Trading Days"), the closing price of the Common Shares on the TSXV
equals or exceeds $0.37. If this occurs, the reduced exercise period of 21 days
will begin seven calendar days after the tenth Premium Trading Day.


The remaining terms and conditions of the Warrants remain unchanged. The Company
will deliver a Notice of Amendment reflecting the amended expiry date to the
registered holders of the Warrants.


About Critical Outcome Technologies Inc. (COTI)

COTI is a leading-edge technology company specializing in accelerating the
discovery and development of small molecules - dramatically reducing the time
and cost to bring new drugs to market. COTI'S proprietary artificial
intelligence system, CHEMSAS(R), utilizes a series of predictive computer models
to identify compounds with a high probability of being successfully developed
from disease specific drug discovery through chemical optimization and
preclinical testing. These compounds are targeted for a variety of diseases,
particularly those for which current treatments are either lacking or
ineffective.


For more information, visit www.criticaloutcome.com.

Follow @CriticalOutcome on Twitter at http://twitter.com/CriticalOutcome.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Critical Outcome Technologies Inc.
Dr. Wayne Danter
President & CEO
519-858-5157
wdanter@criticaloutcome.com
www.criticaloutcome.com


Heisler Communications
Trevor Heisler
Investor Relations
416-500-8061
trevor@heislercommunications.com

Grafico Azioni Cotinga Pharmaceuticals (TSXV:COT)
Storico
Da Nov 2024 a Dic 2024

Grafico Azioni Cotinga Pharmaceuticals (TSXV:COT)
Storico
Da Dic 2023 a Dic 2024